Allergen immunotherapy (AIT) is a safe, effective treatment for allergic rhinoconjunctivitis and allergic asthma. However, AIT's clinical effect is still contested-primarily due to heterogeneity in clinical trial designs, study populations, therapeutic formulations, and efficacy criteria. After discussing current concepts and unmet needs, an 
RCTs) shows that allergen immunotherapy (AIT, whether delivered subcutaneously [SCIT] or sublingually [SLIT] ) is a safe, effective treatment for allergic rhinoconjunctivitis (AR) and allergic asthma. [1] [2] [3] [4] [5] [6] As such, AIT is the only causal treatment option for allergic patients, as it directly targets the pro-inflammatory immune response and thus has disease-modifying properties. [7] [8] [9] Accordingly, AIT has the potential to decrease the neo-sensitization rate (ie, the development of sensitizations to secondary allergens) 10 and has been shown to reduce the risk of developing allergic asthma in AR patients [11] [12] [13] . Accordingly, many medical societies and expert groups have recommended the use of AIT in selected individuals; this mainly covers patients with moderate-to-severe AR who either (i) do not gain sufficient relief from symptomatic medications or (ii) do obtain sufficient relief from symptomatic medications but consider that AIT may counter the severity of their AR symptoms and prevent progression to asthma. [2] [3] [4] [14] [15] [16] [17] Despite these observations, levels of AIT acceptance (both by patients and physicians) are rather modest, as only a minority of eligible patients receive this treatment option. 18, 19 However, there is a high degree of heterogeneity in the clinical trial designs, study populations, therapeutic formulations, and efficacy criteria used in clinical trials on AIT; these include the source of the allergen tested (pollen, house dust mite, animal dander, etc.), the kind of allergen preparation (native allergens vs chemically modified allergens), the administration route (SCIT vs SLIT), and other factors ( Figure 1 ).
Recently, the European Academy of Allergy and Clinical Immunology
(EAACI) published a systematic review and meta-analysis of published clinical trials in AIT and strongly emphasized the need for more thorough standardization in designing future trials. 1 In response to this need, the EAACI also published a position paper on clinical endpoints in AIT trials and notably proposed a harmonized, standardized definition of the combined symptom and medication score (CSMS) for use as a primary endpoint in future pivotal AIT trials. 20 Furthermore, several regulatory authorities, medical societies, and expert groups have issued recommendations on clinical trial design, reporting, and interpretation in the field of allergic disease in general and AIT in particular. [21] [22] [23] [24] [25] [26] [27] [28] These recommendations are valuable but tend to emphasize current good practice, rather than the introduction of truly novel approaches. Hence, an international panel of experts in clinical practice and in the clinical development of AIT products met to discuss current standards and important unmet needs in the conception and design of clinical trials in AIT. The present report highlights the challenges and recommendations identified by the group in ten domains (Table 1) .
| ME TH ODOLOGY
The present expert consensus was achieved through a multistep in- was 30%; based on this definition, 64% of the study participants in the active group and only 32% of the study participants in the placebo group were defined as "AIT responders". 29 Responder analyses should be further investigated in future DBPC RCTs in AIT. The recently published EAACI guideline on AIT in allergic rhinoconjunctivitis stated that the identification of responders (eg, using further stratification approaches) would be useful. • Ten domains on recommendations for improvement of future study designs were outlined.
• Following these recommendations will help to provide novel, ethical ways of reducing bias and heterogeneity in AIT clinical trials.
patients are included out of season and thus are asymptomatic at inclusion, with the expectation that they will develop moderate-tosevere symptoms once allergen exposure starts. Many trials recruit patients with a history of symptoms (ie, retrospective scoring, which has a number of methodological limitations) or with biomarkers of IgE-linked sensitization (high absolute and/or relative allergen-specific IgE serum levels), but this does not guarantee the future occurrence of symptoms. Hence, we suggest that in clinical trials on AIT,
well-defined allergen challenges should be performed on inclusion and then (in extended trials for several years) annually whenever possible. The key to success will be the implementation of a standardized operating procedure by trained, dedicated personnel. 31 With the objective of further (internationally) standardizing and harmonizing allergen challenge methods for future trials in AIT, the EAACI recently published a position paper on the standardization of nasal allergen challenges 32 and a guideline on conjunctival allergen provocation tests in daily practice. 33 However, the type of challenge must be chosen to match the study population's profile; for example, we consider that children are less likely to cooperate during CPTs than during NPTs. Whenever possible, an allergic reaction during a challenge (eg, redness of the conjunctiva in a CPT) should be documented objectively and/or digitally in a format that is compatible with (semi)automated processing (ie, digital photography). 
In multiyear trials, yearly neo-sensitization assays and allergen challenge tests should be performed in all participants.
Most patients consulting a specialist physician for allergic disease will be polysensitized; hence, AIT trials should reflect this by including polysensitized patients. However, polyallergic patients with clinically relevant, overlapping allergen exposures should not be included. In multiyear RCTs, neo-sensitization (using conventional specific IgE and/or multiplex assays) and the possible occurrence of new allergies (using NPT/CPTs) should be yearly monitored in all participants. 3.5 | Domain (v): allergen exposure-differences in regional and seasonal exposure
| Domain (iv): AEC facilities in AIT trials
• Recommendation 5a: For seasonal allergens, peak pollen periods should be primarily investigated. The most accurate assessments of efficacy and safety require the best-defined disease signal. In pivotal Phase III trials, regulatory authorities should allow a primary efficacy criterion focused on the "peak pollen period" (PPP, as defined in the recent EAACI position paper), 37 rather than the pollen season as a whole-the objective being to more closely reflect the patient's unmet needs and clinical demands.
• 21 In some disease areas, however, the European Medicines Agency appears
to be relatively open to adaptations such as sample size reassessment, population enrichment, and the dropping of treatment arms. 39 The potential for the use of adaptive trial designs in AIT should be investigated. Again, upstream, well-grounded dialogue with the regulatory authorities will be essential.
• identified. The placebo effect in AIT is common and relevant. 44 Patients randomized to placebo have even reported up to a 60% decrease in their symptoms. 45, 46 With a view to distinguishing between placebo responders and nonresponders, we encourage research on possible psychological, biochemical, immunological, neural, and even genomic markers of the placebo response. [47] [48] [49] Most of the known predictors of the placebo response are psychological constructs related to goal-seeking, self-esteem, locus of control, optimism, expectation bias, body consciousness, and baseline symptom severity. 47 Manufacturers of AIT products possess large bodies of (partially unpublished) data on patients in active treatment and placebo groups. These datasets could be 51, 52 . In countries regulated by the European Medicines Agency, an applicant for the marketing authorization of an AIT product must submit a pediatric investigation plan (PIP)
for assessment by the Agency's Pediatric Committee. 53 The lack PFAAR ET AL.
| 1779 of an approved PIP will prohibit marketing authorization, even at the national level. Therefore, dialogue with regulatory authorities should be emphasized with regard to selecting robust but practical primary endpoints, decreasing the length of (or omitting) placebo treatment for pediatric patients, and thus giving children easier, faster access to AIT products that have been proven effective in adults. For ethical reasons, we consider that the 5-year DBPC RCT for long-term efficacy in adults with AR should not be mandatory in a PIP for an AIT product. Such a lengthy trial will deprive children in the placebo group of symptom relief and (perhaps just as importantly) a potentially disease-modifying treatment during a critical period in their development. Indeed, a growing body of evidence demonstrates that AIT can counter neo-sensitization and the progression of allergic respiratory disease. [11] [12] [13] [54] [55] [56] [57] Hence, there may be a window of opportunity for AIT in early childhood. High-quality RCTs of AIT products are required in pediatric populations, but more effort should be devoted to developing and validating controlled trials in which the control group receives some form of active treatment (eg, a head-to-head, noninferiority study comparing the investigational formulation with a high-quality, registered comparator), rather than a placebo. Furthermore, waiting for 5-year efficacy data from adult studies prior to starting a pediatric program unnecessarily delays market access to an effective AIT formulation for use in children. This policy will inevitably result in a gap in the availability of AIT products between adult and pediatric patients.
• Recommendation 9b: Primary endpoints other than a CSMS should be considered and further explored in pediatric trials. Although the CSMS has not yet been psychometrically validated, it is still the best primary endpoint in adults for AR. 20 However, there is some room for (i) improvement in the CSMS (eg, by changing the weighting between the symptom score and the medication score) in adults and (ii) the exploration of other systems (a visual analog scale, a disease control score, QoL, etc.), particularly in studies of children and adolescents and in asthma trials 58, 59 .
Scoring a CSMS poses a number of problems in pediatric trials. The WAO criteria are harmonized and standardized for safety reporting in both SCIT and SLIT. 60, 61 More generally, reports of DBPC RCTs should follow the CONSORT guidelines.
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| CONCLUSION S
Evidence from meta-analyses and systematic reviews demonstrate that AIT is a safe and effective treatment for AR and allergic asthma. Even more important, AIT is the only causal treatment option for allergic patients directly targeting the allergic immune reaction, thus bearing disease-modifying properties. Despite these observations, levels of AIT acceptance are rather modest, as only a minority of eligible patients receive this treatment option. This limited acceptance may in part be accentuated by rigid regulatory requirements that prevent more specific investigations of the patients' unmet "real-world" needs and do not sufficiently consider the vast heterogeneity in patient-related and environmental factors.
We strongly believe that addressing these difficulties-by imple- 
